MCID: HPT067
MIFTS: 41

Hepatocellular Adenoma

Categories: Liver diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Hepatocellular Adenoma

MalaCards integrated aliases for Hepatocellular Adenoma:

Name: Hepatocellular Adenoma 12 56 14 69

Characteristics:

Orphanet epidemiological data:

56
hepatocellular adenoma
Age of onset: Adult;

Classifications:

Orphanet: 56  
Rare hepatic diseases


External Ids:

Disease Ontology 12 DOID:0050868
Orphanet 56 ORPHA54272
MESH via Orphanet 43 D018248
UMLS via Orphanet 70 C0206669
ICD10 via Orphanet 34 D13.4

Summaries for Hepatocellular Adenoma

MalaCards based summary : Hepatocellular Adenoma is related to hepatocellular carcinoma and hepatic adenoma, somatic. An important gene associated with Hepatocellular Adenoma is GLUL (Glutamate-Ammonia Ligase), and among its related pathways/superpathways are Metabolism and Cytochrome P450 - arranged by substrate type. The drugs Bevacizumab and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include liver, pancreas and colon, and related phenotypes are homeostasis/metabolism and liver/biliary system

Wikipedia : 72 Hepatocellular adenoma, also hepatic adenoma, or rarely hepadenoma, is an uncommon benign liver tumor... more...

Related Diseases for Hepatocellular Adenoma

Graphical network of the top 20 diseases related to Hepatocellular Adenoma:



Diseases related to Hepatocellular Adenoma

Symptoms & Phenotypes for Hepatocellular Adenoma

MGI Mouse Phenotypes related to Hepatocellular Adenoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.61 CTNNB1 CYP1A1 CYP1A2 FABP1 G6PC GLUL
2 liver/biliary system MP:0005370 9.28 G6PC GLUL HNF1A IL6ST MLXIPL CTNNB1

Drugs & Therapeutics for Hepatocellular Adenoma

Drugs for Hepatocellular Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 42)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 2 216974-75-3
2
Everolimus Approved Phase 2 159351-69-6 6442177
3
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
4
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
5
Sorafenib Approved, Investigational Phase 1, Phase 2 284461-73-0 216239 406563
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
7
Niacin Approved, Investigational, Nutraceutical Phase 1, Phase 2 59-67-6 938
8
Nicotinamide Approved, Nutraceutical Phase 1, Phase 2 98-92-0 936
9 Angiogenesis Inhibitors Phase 2
10 Angiogenesis Modulating Agents Phase 2
11 Anti-Bacterial Agents Phase 2
12 Antibiotics, Antitubercular Phase 2
13 Antibodies Phase 2,Phase 1
14 Antibodies, Monoclonal Phase 2,Phase 1
15 Antifungal Agents Phase 2
16 Anti-Infective Agents Phase 2
17 Endothelial Growth Factors Phase 2
18 Immunoglobulins Phase 2,Phase 1
19 Immunosuppressive Agents Phase 2
20 Liver Extracts Phase 2,Phase 1
21 Mitogens Phase 2
22 Vitamin B Complex Phase 1, Phase 2
23 Micronutrients Phase 1, Phase 2
24 Nicotinic Acids Phase 1, Phase 2
25 Protein Kinase Inhibitors Phase 1, Phase 2
26 Trace Elements Phase 1, Phase 2
27 Vitamins Phase 1, Phase 2
28 Folate Nutraceutical Phase 1, Phase 2
29 Vitamin B9 Nutraceutical Phase 1, Phase 2
30 Vitamin B3 Nutraceutical Phase 1, Phase 2
31
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
32
Pemetrexed Approved, Investigational Phase 1 150399-23-8, 137281-23-3 446556 60843
33
leucovorin Approved, Nutraceutical Phase 1 58-05-9 143 6006
34 Folic Acid Antagonists Phase 1
35 Nucleic Acid Synthesis Inhibitors Phase 1
36 arginine Nutraceutical Phase 1
37
Sunitinib Approved, Investigational 341031-54-7, 557795-19-4 5329102
38
Pancrelipase Approved 53608-75-6
39 Hematinics
40 Gastrointestinal Agents
41 pancreatin
42 Cola Nutraceutical

Interventional clinical trials:


id Name Status NCT ID Phase Drugs
1 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
2 Internal Radiation Therapy for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus Standard Dosimetry Recruiting NCT02582034 Phase 2
3 Sorafenib and TRC105 in Hepatocellular Cancer Active, not recruiting NCT01306058 Phase 1, Phase 2 TRC 105;Sorafenib
4 Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Recruiting NCT02029690 Phase 1 ADI-PEG 20
5 Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions. Completed NCT01043523 Gadoxetic Acid Disodium (Eovist, BAY86-4873)
6 Quality of Life After Liver Resection Completed NCT00681499
7 A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. Completed NCT00428220 sunitinib
8 Observational Study of Biomarker During Liver Surgery Recruiting NCT02102971
9 LRP1 and Colon Cancer Recruiting NCT02788669
10 Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Sur Recruiting NCT01416714

Search NIH Clinical Center for Hepatocellular Adenoma

Genetic Tests for Hepatocellular Adenoma

Anatomical Context for Hepatocellular Adenoma

MalaCards organs/tissues related to Hepatocellular Adenoma:

39
Liver, Pancreas, Colon, Endothelial, Placenta, Bone, Bone Marrow

Publications for Hepatocellular Adenoma

Articles related to Hepatocellular Adenoma:

(show top 50) (show all 268)
id Title Authors Year
1
Hepatocellular adenoma: Classification, variants and clinical relevance. ( 28131467 )
2017
2
Short-term outcomes of laparoscopic vs. open liver resection for hepatocellular adenoma: a multicenter propensity score adjustment analysis by the AFC-HCA-2013 study group. ( 28281121 )
2017
3
Hepatocellular adenoma in a European flatfish (Limanda limanda): Genetic alterations in laser-capture micro-dissected tissue and global transcriptomic approach. ( 28473212 )
2017
4
Argininosuccinate synthase 1 (ASS1): A marker of unclassified hepatocellular adenoma and high bleeding risk. ( 28646562 )
2017
5
Response to "Quantitative analysis of hepatocellular adenoma and focal nodular hyperplasia in the hepatobiliary phase: External validation of llcer method using gadobenate dimeglumine as contrast agent". ( 28580722 )
2017
6
Management and outcome of hepatocellular adenoma with massive bleeding at presentation. ( 28740346 )
2017
7
Molecular classification of hepatocellular adenoma in clinical practice. ( 28733222 )
2017
8
Retrospective study on timing of resection of hepatocellular adenoma. ( 28857134 )
2017
9
Exome analysis of the evolutionary path of hepatocellular adenoma-carcinoma transition, vascular invasion and brain dissemination. ( 28323122 )
2017
10
Hepatocellular adenoma with severe fatty change in a male Spontaneously Diabetic Torii rat. ( 28190927 )
2017
11
Quantitative analysis Of hepatocellular adenoma and focal nodular hyperplasia in the hepatobiliary phase: External validation of LLCER method using gadobenate dimeglumine as contrast agent. ( 28589549 )
2017
12
Screening the key genes of hepatocellular adenoma via microarray analysis of DNA expression and methylation profiles. ( 28943905 )
2017
13
Men with biopsy-confirmed hepatocellular adenoma have a high risk of progression to hepatocellular carcinoma: AA nationwide population-based study. ( 28317318 )
2017
14
A cost-effectiveness analysis of the diagnostic strategies for differentiating focal nodular hyperplasia from hepatocellular adenoma. ( 28726119 )
2017
15
Malignant potential of hepatocellular adenoma. ( 28635168 )
2017
16
Diagnostic Value of Gd-EOB-DTPA-MRI for Hepatocellular Adenoma: A Meta-Analysis. ( 28607606 )
2017
17
Systematic review: benefits and harms of transarterial embolisation for treating hepatocellular adenoma. ( 28318052 )
2017
18
Intravoxel incoherent motion and dynamic contrast-enhanced MRI for differentiation between hepatocellular adenoma and focal nodular hyperplasia. ( 28590780 )
2017
19
Inflammatory and multiple hepatocellular adenoma are associated with a higher BMI. ( 28704224 )
2017
20
Correlation of exon 3 I^-catenin mutations with glutamine synthetase staining patterns in hepatocellular adenoma and hepatocellular carcinoma. ( 27469330 )
2016
21
Response to 'The management of hepatocellular adenoma in obese patients: issues to consider'. ( 26767571 )
2016
22
A Pigmented hepatocellular adenoma with I^-catenin activation: case report and literature review. ( 27236161 )
2016
23
Malignant Transformation of Hepatocellular Adenoma. ( 27988517 )
2016
24
Contrast-enhanced ultrasonographic findings of serum amyloid A-positive hepatocellular neoplasm: Does hepatocellular adenoma arise in cirrhotic liver? ( 27660679 )
2016
25
Combined use of heat-shock protein 70 and glutamine synthetase is useful in the distinction of typical hepatocellular adenoma from atypical hepatocellular neoplasms and well-differentiated hepatocellular carcinoma. ( 26769138 )
2016
26
Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma. ( 27189732 )
2016
27
Malignant transformation of hepatocellular adenoma with bone marrow metaplasia arising in glycogen storage disease type I: A case report. ( 27900094 )
2016
28
Hepatocellular adenoma among adult survivors of childhood and young adult cancer. ( 27781382 )
2016
29
Hepatocellular Adenoma of the Placenta With Updated Immunohistochemical and Molecular Markers: A Case Report. ( 27106781 )
2016
30
Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. ( 27939373 )
2016
31
Evidence of good prognosis of hepatocellular adenoma in post-menopausal women. ( 27524464 )
2016
32
Hepatocellular adenoma with malignant transformation in a patient with neonatal portal vein thrombosis. ( 27042773 )
2016
33
Distinction Between Inflammatory Hepatocellular Adenoma and Mass Effect on Liver Sampling. ( 27989788 )
2016
34
Hepatocellular adenoma: comparison between real-time contrast-enhanced ultrasound and dynamic computed tomography. ( 27386395 )
2016
35
Hepatocellular adenoma: when and how to treat? Update of current evidence. ( 27803743 )
2016
36
Touch cytology smear of an inflammatory hepatocellular adenoma displaying an unusual pattern: A case report. ( 27434199 )
2016
37
Hepatoblastoma Arising in a Pigmented I^-catenin-activated Hepatocellular Adenoma: Case Report and Review of the Literature. ( 27096257 )
2016
38
PET-avid hepatocellular adenomas: incidental findings associated with HNF1-I+ mutated lesions. ( 26776850 )
2016
39
European experience of 573 liver resections for hepatocellular adenoma: a cross-sectional study by the AFC-HCA-2013 study group. ( 27593592 )
2016
40
Ultrasound features of hepatocellular adenoma and the additional value of contrast-enhanced ultrasound. ( 26818543 )
2016
41
Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis. ( 26961851 )
2016
42
Outcomes of liver resection for haemorrhagic hepatocellular adenoma. ( 26805568 )
2016
43
NF-I_B/RelA and Nrf2 cooperate to maintain hepatocyte integrity and to prevent development of hepatocellular adenoma. ( 26348541 )
2015
44
Hepatocellular adenoma: An update. ( 26557953 )
2015
45
Hepatocellular adenoma with malignant transformation in male patients with non-cirrhotic livers. ( 26058379 )
2015
46
Focal nodular hyperplasia and hepatocellular adenoma: The value of shear wave elastography for differential diagnosis. ( 26299323 )
2015
47
Morphologic and Molecular Features of Hepatocellular Adenoma with Gadoxetic Acid-enhanced MR Imaging. ( 25985059 )
2015
48
Giant hepatocellular adenoma with peliosis hepatis in a child: A diagnostic dilemma. ( 27522744 )
2015
49
Gd-EOB-DTPA-Enhanced Magnetic Resonance Findings of a Giant Inflammatory Hepatocellular Adenoma: a Case Report and Review of the Literature. ( 25894634 )
2015
50
Focal Nodular Hyperplasia and Hepatocellular Adenoma: Accuracy of Gadoxetic Acid-enhanced MR Imaging-A Systematic Review. ( 26599935 )
2015

Variations for Hepatocellular Adenoma

Expression for Hepatocellular Adenoma

Search GEO for disease gene expression data for Hepatocellular Adenoma.

Pathways for Hepatocellular Adenoma

Pathways related to Hepatocellular Adenoma according to GeneCards Suite gene sharing:

(show all 25)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 CYP1A1 CYP1A2 CYP3A4 FABP1 G6PC GLUL
2
Show member pathways
13 CYP1A1 CYP1A2 CYP3A4 GSTP1 UGT2B7
3
Show member pathways
12.35 CYP1A1 CYP1A2 CYP3A4 GSTP1 UGT2B7
4 12.26 CYP1A2 CYP3A4 FABP1 HNF1A
5
Show member pathways
12.01 CYP1A1 CYP1A2 CYP3A4
6 11.88 CTNNB1 HNF1A IL6ST
7 11.84 CTNNB1 HNF1A IL6ST
8
Show member pathways
11.52 CYP1A1 CYP1A2 CYP3A4 GSTP1
9
Show member pathways
11.5 CYP1A1 CYP1A2 CYP3A4
10
Show member pathways
11.36 CYP1A2 CYP3A4 UGT2B7
11
Show member pathways
11.36 CYP1A1 CYP1A2 CYP3A4 UGT2B7
12
Show member pathways
11.31 CYP1A1 CYP1A2 CYP3A4
13
Show member pathways
11.24 CYP1A1 CYP1A2 CYP3A4 UGT2B7
14 11.19 CYP1A1 CYP1A2
15 11.17 CYP3A4 MLXIPL
16 11.15 CYP1A2 CYP3A4
17
Show member pathways
11.02 CYP1A2 CYP3A4
18
Show member pathways
11 CYP3A4 UGT2B7
19 10.94 CYP1A2 CYP3A4
20 10.87 CYP3A4 UGT2B7
21
Show member pathways
10.79 CYP1A1 CYP1A2 CYP3A4 UGT2B7
22 10.7 CYP3A4 GSTP1
23 10.62 CYP1A1 CYP1A2
24 10.3 CYP1A1 CYP1A2 CYP3A4 GSTP1
25 10.16 CYP3A4 UGT2B7

GO Terms for Hepatocellular Adenoma

Cellular components related to Hepatocellular Adenoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.62 CTNNB1 FABP1 GLUL HNF1A
2 endoplasmic reticulum membrane GO:0005789 9.55 CYP1A1 CYP1A2 CYP3A4 G6PC UGT2B7
3 transcription factor complex GO:0005667 9.43 CTNNB1 HNF1A MLXIPL
4 intracellular membrane-bounded organelle GO:0043231 9.43 CYP1A1 CYP1A2 CYP3A4 G6PC GLUL UGT2B7
5 organelle membrane GO:0031090 8.92 CYP1A1 CYP1A2 CYP3A4 UGT2B7

Biological processes related to Hepatocellular Adenoma according to GeneCards Suite gene sharing:

(show all 27)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.92 CTNNB1 FABP1 IL6ST MLXIPL
2 regulation of gene expression GO:0010468 9.8 CTNNB1 CYP1A2 G6PC
3 glucose homeostasis GO:0042593 9.75 G6PC HNF1A MLXIPL
4 response to estradiol GO:0032355 9.73 CTNNB1 CYP1A2 GSTP1
5 xenobiotic metabolic process GO:0006805 9.69 CYP1A2 CYP3A4 GSTP1
6 glycogen metabolic process GO:0005977 9.63 G6PC IL6ST
7 response to immobilization stress GO:0035902 9.62 CYP1A1 CYP1A2
8 bone resorption GO:0045453 9.61 CTNNB1 HNF1A
9 response to food GO:0032094 9.61 CYP1A1 G6PC
10 epoxygenase P450 pathway GO:0019373 9.6 CYP1A1 CYP1A2
11 androgen metabolic process GO:0008209 9.59 CYP3A4 UGT2B7
12 cellular response to copper ion GO:0071280 9.58 CYP1A1 CYP1A2
13 exogenous drug catabolic process GO:0042738 9.57 CYP1A2 CYP3A4
14 vitamin D metabolic process GO:0042359 9.55 CYP1A1 CYP3A4
15 hydrogen peroxide biosynthetic process GO:0050665 9.54 CYP1A1 CYP1A2
16 omega-hydroxylase P450 pathway GO:0097267 9.52 CYP1A1 CYP1A2
17 oxidative demethylation GO:0070989 9.49 CYP1A2 CYP3A4
18 drug catabolic process GO:0042737 9.46 CYP1A2 CYP3A4
19 lipid hydroxylation GO:0002933 9.43 CYP1A1 CYP3A4
20 monoterpenoid metabolic process GO:0016098 9.4 CYP1A2 CYP3A4
21 steroid catabolic process GO:0006706 9.37 CYP1A2 CYP3A4
22 drug metabolic process GO:0017144 9.33 CYP1A1 CYP1A2 CYP3A4
23 porphyrin-containing compound metabolic process GO:0006778 9.32 CYP1A1 CYP1A2
24 dibenzo-p-dioxin metabolic process GO:0018894 9.26 CYP1A1 CYP1A2
25 toxin metabolic process GO:0009404 9.18 CYP1A2
26 steroid metabolic process GO:0008202 9.02 CYP1A1 CYP1A2 CYP3A4 G6PC UGT2B7
27 heterocycle metabolic process GO:0046483 8.96 CYP1A2 CYP3A4

Molecular functions related to Hepatocellular Adenoma according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.78 CTNNB1 CYP1A1 CYP1A2 CYP3A4
2 iron ion binding GO:0005506 9.69 CYP1A1 CYP1A2 CYP3A4
3 heme binding GO:0020037 9.67 CYP1A1 CYP1A2 CYP3A4
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.63 CYP1A1 CYP1A2 CYP3A4
5 monooxygenase activity GO:0004497 9.54 CYP1A1 CYP1A2 CYP3A4
6 steroid hydroxylase activity GO:0008395 9.52 CYP1A1 CYP3A4
7 estrogen 16-alpha-hydroxylase activity GO:0101020 9.43 CYP1A1 CYP3A4
8 oxygen binding GO:0019825 9.43 CYP1A1 CYP1A2 CYP3A4
9 demethylase activity GO:0032451 9.4 CYP1A1 CYP1A2
10 caffeine oxidase activity GO:0034875 9.32 CYP1A2 CYP3A4
11 vitamin D 24-hydroxylase activity GO:0070576 9.16 CYP1A1 CYP3A4
12 aromatase activity GO:0070330 9.13 CYP1A1 CYP1A2 CYP3A4
13 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 8.8 CYP1A1 CYP1A2 CYP3A4

Sources for Hepatocellular Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....